KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbCellera Biologics (ABCL) Change in Receivables: 2019-2024

Historic Change in Receivables for AbCellera Biologics (ABCL) over the last 6 years, with Dec 2024 value amounting to $75.1 million.

  • AbCellera Biologics' Change in Receivables fell 82.68% to $3.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $36.8 million, marking a year-over-year decrease of 43.09%. This contributed to the annual value of $75.1 million for FY2024, which is 63.54% up from last year.
  • As of FY2024, AbCellera Biologics' Change in Receivables stood at $75.1 million, which was up 63.54% from $45.9 million recorded in FY2023.
  • AbCellera Biologics' 5-year Change in Receivables high stood at $75.1 million for FY2024, and its period low was $5.5 million during FY2020.
  • Over the past 3 years, AbCellera Biologics' median Change in Receivables value was $45.9 million (recorded in 2023), while the average stood at $47.9 million.
  • Its Change in Receivables has fluctuated over the past 5 years, first surged by 583.85% in 2021, then plummeted by 39.24% in 2022.
  • Yearly analysis of 5 years shows AbCellera Biologics' Change in Receivables stood at $5.5 million in 2020, then skyrocketed by 583.85% to $37.4 million in 2021, then tumbled by 39.24% to $22.7 million in 2022, then surged by 102.21% to $45.9 million in 2023, then skyrocketed by 63.54% to $75.1 million in 2024.